Ref: MR/01/2024-2025 November 09, 2024

Media Release

REMUS PHARMACEUTICALS LIMITED ANNOUNCES FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2024

November 09, 2024, Ahmedabad: Remus Pharmaceuticals Limited ("Remus") (NSE SYMBOL: **REMUS**), has reported its Un-Audited Standalone and Consolidated Financial Results for the Half Year ended September 30, 2024. The Company has posted strong performance for H1 FY25 and this trend sets the stage for remaining year's performance.

FINANCIAL SUMMARY (All numbers are in Rs. Lakhs, except margins)

Comprehensive Consolidated Financial Overview

- Remus' total revenue for the H1 FY25 increased to Rs. 27,555.54 Lakhs as compared to Rs. 3,069.9 Lakhs for the same period in H1 FY24 and Rs. 18,720.01 Lakhs for the immediately preceding half year ended March 31, 2024;
- The total revenue has grown by 797.60% between H1 FY25 and H1 FY24 and by 47.20 % between H1 FY25 and immediately preceding half year ended March 31, 2024;
- Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA") has increased to Rs. 2,337.8 Lakhs in H1 FY25 as compared to Rs. 1,092.46 Lakhs in H1 FY24 showing a growth of 113.99% between H1 FY25 and H1 FY24;
- Profit After Taxes ("PAT") has increased to Rs. 1,401.12 Lakhs in H1 FY25 as compared to Rs. 546.76 Lakhs in H1 FY24 showing a strong growth of 148.09% between H1 FY25 and H1 FY24.

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "Remus's financial performance during the First half Year has met our expectations, reflecting our team's dedication and hard work. We are excited about the continued growth and the opportunities. Looking ahead, Remus remains optimistic about the second half of the year, with plans to enhance customer offerings and to enter new markets"

About Remus Pharmaceuticals Limited (NSE SYMBOL: REMUS)

Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. We also deal in API (Active Pharmaceutical Ingredient), along with providing technical consultancy services to various distributors for preparation of reports on the dossiers of the products, to be registered by the said distributors in various countries.

Remus®
Dedicated to Global Healthcare

Safe Harbor

This document includes certain forward-looking statements which are tentative, based on current expectations of the management of Remus Pharmaceuticals Limited or any of its subsidiaries ("Remus"). These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors, exchange rate fluctuations, cash flow projections, interest, and other costs. Remus, its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Remus does not undertake any obligation to revise or update any forward-looking statement that may be made from time to time by or on behalf of the Company including to reflect actual results, changes in assumptions or changes in factors affecting these statements.

Remus Pharmaceuticals Limited
REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857
E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536